Cat. No. |
Product Name |
Information |
PC-60398 |
G1T38 dihydrochloride
CDK4/6 inhibitor
|
Lerociclib (G1T38) dihydrochloride is a potent and selective inhibitor of CDK4/6 with biochemical IC50 of 1 nM and 2 nM for CDK4/cyclin D1 and CDK6/cyclin D3, respectively. |
PC-60397 |
G1T38
CDK4/6 inhibitor
|
G1T38 (Lerociclib, G1T 38) is a novel, potent and selective inhibitor of CDK4/6 with biochemical IC50 of 1 nM and 2 nM for CDK4/cyclin D1 and CDK6/cyclin D3, respectively. |
PC-60395 |
Trilaciclib
CDK4/6 inhibitor
|
Trilaciclib (G1T28) is a novel, potent and selective inhibitor of CDK4/6 with biochemical IC50 of 1 nM and 4 nM for CDK4/cyclin D1 and CDK6/cyclin D3, respectively. |
PC-60329 |
NVP-2
CDK9 inhibitor
|
NVP-2 is a potent, selective, ATP-competitive CDK9 inhibitor with IC50 of <0.514 nM (CDK9/CyclinT). |
PC-70170 |
GW-8510
CDK2 inhibitor
|
GW-8510 (GW8510) is a potent, selective inhibitor of CDK2 with IC50 of 10 nM. |
PC-70116 |
NU-6027
CDK1/2 inhibitor
|
NU-6027 (NU6027) is an ATP-competitive inhibitor of CDK1 and CDK2 with Ki of 2.5 uM and 1.3 uM respectively. |
PC-60298 |
MSC2530818
CDK8 inhibitor
|
MSC-2530818 (MSC 2530818, MSC2530818) is a potent, selective, and orally bioavailable CDK8 inhibitor with IC50 of 2.6 nM. |
PC-45559 |
NU-6300
CDK2 inhibitor
|
NU-6300 is the first covalent, irreversible, ATP-Competitive CDK2 inhibitor with Ki of 6 nM. |
PC-44628 |
Senexin-A
CDK8/CDK19 inhibitor
|
Senexin-A is a selective inhibitor of CDK8 (IC50=0.28 uM) and CDK19, inhibits CDK8 and CDK19 ATP site binding with Kd50 of 0.83 uM and 0.31 uM, respectively. |
PC-45491 |
SU-9516
CDK2 inhibitor
|
SU-9516 is a potent, selective CDK2 inhibitor with IC50 of 22 nM. |
PC-46009 |
THZ1 hydrochloride
CDK7 inhibitor
|
THZ1 hydrochloride is a potent, selective, covalent CDK7 inhibitor with IC50 of 3.2 nM. |
PC-46008 |
THZ1
CDK7 inhibitor
|
THZ1 is a potent, selective, covalent CDK7 inhibitor with IC50 of 3.2 nM, also weakly inhibits CDK12 with IC50 of 250 nM. |